Uremic Toxin Clearance and Cardiovascular Toxicities

Area of Science:

• Nephrology
• Cardiovascular Medicine
• Toxicology

Background:

• Uremic solutes are implicated in cardiovascular disease (CVD) in patients with renal insufficiency.
• Specific solutes like indoxyl sulfate (IS), p-cresol sulfate (PCS), phenylacetylglutamine (PAG), trimethylamine-n-oxide (TMAO), and kynurenine are associated with CVD.
• These solutes exhibit diverse clearance mechanisms via native kidneys and renal replacement therapy.

Purpose of the Study:

• To review the clearance mechanisms of selected uremic solutes linked to cardiovascular disease.
• To elucidate how chronic kidney disease (CKD) and dialysis affect the plasma levels of these solutes.
• To discuss potential strategies for reducing uremic toxin levels.

Main Methods:

• Review of existing literature on uremic solute clearance in renal insufficiency.
• Analysis of clearance mechanisms for protein-bound (IS, PCS) and non-protein-bound (PAG, TMAO) solutes.
• Comparison of solute levels and clearance in CKD patients versus dialysis patients.

Main Results:

• IS and PCS are protein-bound, cleared by tubular secretion; PAG and TMAO are non-protein-bound, also cleared by tubular secretion.
• CKD reduces renal clearance of IS, PCS, PAG, and TMAO, leading to increased plasma levels.
• Dialysis patients exhibit even higher levels of these solutes compared to advanced CKD patients due to low dialytic-to-native kidney clearance ratios.

Conclusions:

• Reduced renal clearance is the primary driver of elevated uremic solute levels in CKD.
• Intermittency of dialysis, increased solute production, and non-renal clearance limit the effectiveness of renal replacement therapy.
• Inhibiting uremic solute production may offer a more effective future strategy for managing cardiovascular risk in CKD.